NexImmune, Inc. (NEXI)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Aug 25, 2026, 4:00 PM EST
NexImmune Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 10.62 | 13.13 | 16.31 | 15.8 | 10.28 | 5.98 |
Research & Development | 6.44 | 16.05 | 46.77 | 37.46 | 17.57 | 14.9 |
Operating Expenses | 17.06 | 29.18 | 63.08 | 53.26 | 27.85 | 20.89 |
Operating Income | -17.06 | -29.18 | -63.08 | -53.26 | -27.85 | -20.89 |
Interest Expense | - | - | - | -0.91 | -1.68 | -0.01 |
Interest & Investment Income | 0.25 | 0.7 | 0.66 | 0.05 | 0.02 | 0.25 |
Other Non Operating Income (Expenses) | 0.77 | 0.03 | -0.09 | 2.36 | -0.35 | 0.09 |
EBT Excluding Unusual Items | -16.05 | -28.45 | -62.51 | -51.75 | -29.87 | -20.55 |
Merger & Restructuring Charges | -3.1 | -3.1 | - | - | - | - |
Gain (Loss) on Sale of Assets | -1.37 | -0.69 | - | - | - | - |
Asset Writedown | -0.1 | -0.1 | - | - | - | - |
Other Unusual Items | - | - | - | 0.84 | - | - |
Pretax Income | -20.62 | -32.34 | -62.51 | -50.9 | -29.87 | -20.55 |
Net Income | -20.62 | -32.34 | -62.51 | -50.9 | -29.87 | -20.55 |
Preferred Dividends & Other Adjustments | - | - | - | 0.38 | 3.28 | 2.66 |
Net Income to Common | -20.62 | -32.34 | -62.51 | -51.28 | -33.15 | -23.21 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 |
Shares Change | 15.46% | 9.05% | 19.19% | 1508.68% | 1.16% | 10.53% |
EPS (Basic) | -17.39 | -30.82 | -64.95 | -63.51 | -660.39 | -467.70 |
EPS (Diluted) | -17.39 | -30.82 | -64.95 | -63.51 | -660.39 | -467.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Free Cash Flow | -17.61 | -31.48 | -52.45 | -48.14 | -27.27 | -20.66 |
Free Cash Flow Per Share | -14.85 | -30.00 | -54.50 | -59.62 | -543.29 | -416.40 |
EBITDA | -16.38 | -28.16 | -62.09 | -52.39 | -27.23 | -20.45 |
D&A For EBITDA | 0.68 | 1.02 | 0.99 | 0.87 | 0.62 | 0.44 |
EBIT | -17.06 | -29.18 | -63.08 | -53.26 | -27.85 | -20.89 |